PARIS, France (AFP) — French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specializes in treatments for hemophilia and rare blood disorders, for $11.6 billion. Sanofi’s chief executive Olivier Brandicourt said the acquisition “enhances its presence in specialty care and leadership in rare diseases… and creates a platform for growth in other rare blood disorders.” The purchase should also translate into a boost in profits per […]